Gitnux/Report 2026

Diabetes Industry Statistics

The diabetes-care market is projected at $31.63 billion in 2026, explore the figures behind growth, companies and trends across medicines, devices and monitoring.
26Statistics
27Sources
6Sections
1Visuals
16mRead
Diabetes Industry Statistics
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 32 days

01 Industry overview

The diabetes industry at a glance

Diabetes-related health spending surpassed $1 trillion in 2024, while 589 million adults lived with diabetes and the total is projected to reach 853 million by 2050. Three in four adults with diabetes live in low- and middle-income countries, and GLP-1 competition intensifies alongside expanding indications and safety-labeling requirements.

$1T+[12]
Diabetes spending, 2024
589M[13]
Adults with diabetes, 2024
43%[14]
Novo GLP-1 volume share, 2025
7.1/1,000[15]
U.S. incidence rate, 2025
Market size
Global diabetes-related health expenditure surpassed $1 trillion in 2024, representing 12% of global health expenditure. This is the latest broad measure of the economic size of the diabetes industry and care ecosystem.[12]
Forecast & CAGR
The number of adults with diabetes is projected to rise from 589 million in 2024 to 853 million in 2050, an increase of about 45%. This corresponds to an approximate 1.4% compound annual growth rate over 2024–2050, calculated from the IDF estimates.[13]
Market share & regions
Three in four adults with diabetes live in low- and middle-income countries. In 2024, age-standardised prevalence was highest in middle-income countries at 11.46%, compared with 10.21% in high-income countries and 7.47% in low-income countries.[12][16]
Segmentation
The disease burden is primarily concentrated in adults aged 20–79, the population covered by the IDF’s principal estimate. In 2024, 158 million adults with diabetes were aged over 65, while an estimated 9.1 million people were living with type 1 diabetes.[13]
Key players & concentration
The GLP-1 segment is concentrated among a small number of large pharmaceutical companies. Novo Nordisk reported close to 43% of global GLP-1 volumes in 2025 and reached 42 million people with its diabetes portfolio.[14]
Pricing
U.S. insulin affordability improved by 2025: average monthly out-of-pocket spending fell to $12.04 for Medicare users and $18.26 for commercially insured users, compared with $42.79 and $39.13, respectively, in 2018. Cash and patient-assistance purchases averaged $70.93 per month in 2025.[17]
Trends, drivers & challenges
The main growth driver is the rising prevalence of diabetes: 589 million adults had the condition in 2024, and 252 million were unaware they had it. Key challenges include diagnosis gaps, unequal access, and rising demand for advanced medicines and monitoring products.[13][12]
Consumer behavior & competition
In the United States, 40.1 million people of all ages had diagnosed or undiagnosed diabetes in 2023, including 11.0 million adults with undiagnosed diabetes. Competition is intensifying in GLP-1 therapies, where Novo Nordisk reported 43% of global volumes in 2025 and Eli Lilly is a major rival.[18][14]
Regulation
Regulatory activity remains focused on expanding indications and managing safety. The FDA’s approved GLP-1 receptor agonist list includes Ozempic, Rybelsus, Wegovy, Mounjaro, Zepbound and the 2026 approval Foundayo; the agency also issued new GLP-1 safety-labeling requirements in 2026.[19]
Latest news
In October 2026, the FDA approved Awiqli, insulin icodec-abae, as the first once-weekly insulin for type 2 diabetes in pediatric patients. The FDA’s 2026 notable-approvals list also records Foundayo, orforglipron, as an approved GLP-1 receptor agonist.[19]

02 Ranking

Top 10 Companies in the Diabetes Industry

The leading companies in the diabetes industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 21, 2026 · Next review December 21, 2026

Verdict

Eli Lilly and Company stands out for diabetes and cardiometabolic medicines because it reported $65.179 billion in 2025 revenue driven partly by Mounjaro, while Insulet focuses on tubeless insulin delivery since Omnipod is available in 25 countries.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in diabetes medicines

    Eli Lilly and Company

    US

    Ranked #1 · 9.9 · Diabetes medicines

    Why we picked it: It reports $65.179 billion in 2025 revenue and an operating margin of 40.4% tied to its diabetes portfolio.

  2. Leader in insulin delivery devices

    Insulet

    US

    Ranked #2 · 9.2 · Insulin delivery devices

    Why we picked it: Its tubeless wearable platform, Omnipod, reaches 25 countries and supports a 17.5% operating margin.

  3. Leader in diabetes diagnostics

    Roche

    CH

    Ranked #3 · 9.1 · Diabetes diagnostics

    Why we picked it: Its Diabetes Care business spans blood-glucose monitoring products within diagnostics and medicines.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the diabetes industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Diabetes medicines · US

9.9
2

Insulet

Insulin delivery devices · US

9.2
3

Roche

Diabetes diagnostics · CH

9.1
4

Dexcom

Continuous glucose monitoring · US

9.0
5

Novo Nordisk

Diabetes medicines · DK

8.9
6

Sanofi

Insulin and diabetes medicines, global · FR

8.7
7

MiniMed Group

Insulin pumps and automated insulin delivery · US

8.6
8

MannKind

Inhaled insulin and wearable insulin delivery · US

8.6
9

Ypsomed

Insulin delivery and self-injection systems · CH

8.4
10

PHC Holdings

Blood glucose monitoring and diabetes devices · JP

7.6

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 21, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 21). Top 10 companies in the diabetes industry. In Diabetes Industry Statistics. Gitnux. https://gitnux.org/diabetes-industry-statistics/#top-companies

report visual · Comparison

Number of adults aged 20–79 years with diabetes

China leads with 148 millions.

China148 millions
India89.8 millions
United States of America38.5 millions
Pakistan34.5 millions
Indonesia20.4 millions
Brazil16.6 millions
source-verifieddiabetesatlas.org

04 Statistics

Market Intelligence

These figures anchor the diabetes ecosystem across treated-adult spending and service-based diabetes-care definitions. U.S. diabetes-treatment healthcare expenditures reached $153.2 billion in 2021–2022.

Market size and service revenue in the diabetes industry

  • $153.2 billion in annual U.S. diabetes-treatment healthcare expenditures in 2021–2022, covering treated adults in the civilian noninstitutionalized population; the estimate includes services and prescription medications.[1]
  • $29.09 billion was the 2025 global diabetes-care market, defined as revenues from insulin therapy, medication management, nutrition and diet planning, lifestyle support, telemedicine and remote monitoring services.[2]

Growth forecasts for the diabetes industry

  • $31.63 billion is projected for the global diabetes-care market in 2026, defined by the source as insulin therapy, medication management, nutrition, lifestyle support, telemedicine and remote-monitoring services; forecast CAGR is 8.6% for 2026–2030.[2]
  • $56.62 billion is projected for the U.S. diabetes-management market in 2034, representing a 56.5% increase from the source’s 2025 base estimate of $36.19 billion; the category includes products, treatments and management services.[3]
  • $38.03 billion is projected for the U.S. diabetes-management market in 2026, within a 2026–2034 forecast that reaches $56.62 billion in 2034; the source covers products, treatments and management services.[3]
  • $43.97 billion is projected for the global diabetes-care market in 2030, under the source’s service-based diabetes-care definition; projected CAGR is 8.6% for 2026–2030.[2]

05 Statistics

Operating Benchmarks

Service utilization shows where care delivery capacity concentrates in the United States. In 2025, 77% of diabetes-care and education specialist practices independently provided continuous-glucose-monitoring services.

Operating metrics used in the diabetes industry

  • 43.2% of U.S. commercial type 2 diabetes patients received an ophthalmologic exam in 2023, according to the Heartland Healthcare Coalition Diabetes Report’s national service-utilization measure.[4]
  • 77% of U.S. diabetes-care and education specialist practices independently provided continuous-glucose-monitoring services in 2025; the ADCES survey covered practicing diabetes-care and education specialists.[5]
  • 85.0% of U.S. commercial type 2 diabetes patients received an A1c test in 2023, according to the Heartland Healthcare Coalition Diabetes Report’s national service-utilization measure.[4]
  • 77% of U.S. diabetes-care and education specialist practices independently provided insulin adjustment, initiation or titration in 2025; the ADCES survey covered practicing diabetes-care and education specialists.[5]

06 Statistics

Delivery & Operations

Team staffing measures the operational footprint of diabetes-care delivery settings. In 2025, 68% of diabetes care and education specialist practices included a registered nurse on the diabetes care team.

Delivery capacity and installed base in the diabetes industry

  • 68% of U.S. diabetes care and education specialist practices included a registered nurse on the diabetes care team in 2025.[5]
  • 19,255 professionals held the Certified Diabetes Care and Education Specialist credential in April 2025, representing qualified diabetes-care delivery capacity in the United States.[6]
  • 66% of U.S. diabetes care and education specialist practices included a registered dietitian or nutritionist on the diabetes care team in 2025.[5]

07 Statistics

People & Workforce

Credential counts and primary disciplines indicate workforce structure and delivery specialization. In April 2025, 19,255 professionals held the Certified Diabetes Care and Education Specialist credential.

Skills and certification in the diabetes industry

  • 19,255 professionals held the Certified Diabetes Care and Education Specialist credential in April 2025, indicating the size of the principal U.S. diabetes-care specialist credential population.[6]
  • 46% of U.S. diabetes care and education specialist survey respondents identified nursing as their primary discipline in 2025.[5]
  • 39% of U.S. diabetes care and education specialist survey respondents identified dietetics or nutrition as their primary discipline in 2025.[5]

08 Statistics

Pricing

Reimbursement and charges quantify cost-to-care dynamics for diabetes training and related services. Medicare national average reimbursement was $53.05 in 2025 for one individual diabetes self-management-training unit of 30 minutes.

Fees and price levels in the diabetes industry

  • $15.20 was the 2025 Medicare national average reimbursement per patient for one group diabetes self-management-training unit of 30 minutes.[7]
  • $2,923 was the 2023 national professional office/clinic charge per commercial type 2 diabetes patient per year, versus $2,768 in Florida; the report defines charges as provider-generated professional charges.[8]
  • $53.05 was the 2025 Medicare national average reimbursement for one individual diabetes self-management-training unit of 30 minutes.[7]
  • $5,244 was the 2023 national professional inpatient charge per commercial type 2 diabetes patient per year, compared with $5,113 in Florida.[8]

09 Statistics

Risk & Compliance

Compliance rules set timing and retention boundaries for diabetes-related records and notifications. HIPAA Security Rule documentation requires a minimum 6 years retention period.

Regulation and licensing in the diabetes industry

  • 2 hours per calendar year is the Medicare-covered follow-up medical-nutrition-therapy limit after the initial coverage year for eligible people with diabetes.[9]
  • 80% of the lesser of actual charges or 85% of the physician fee-schedule amount is the Medicare payment rule for qualified nonphysician medical-nutrition-therapy professionals under 42 CFR §414.64.[10]
  • 3 hours is the Medicare-covered initial medical-nutrition-therapy limit for beneficiaries with diabetes during the first coverage year under 42 CFR Part 410.[9]

Client data and confidentiality in the diabetes industry

  • 6 years is the minimum retention period for required HIPAA Security Rule documentation, measured from creation or the date it was last in effect, whichever is later.[10]
  • 60 calendar days is the maximum period for HIPAA covered entities and business associates to notify affected individuals after discovering a breach of unsecured protected health information.[11]
  • 500 individuals is the threshold at which HIPAA-covered diabetes-care providers must notify the HHS Secretary without unreasonable delay and within 60 days of discovering a breach.[11]

Key questions about the diabetes industry

What is the current economic size of the diabetes industry?
Diabetes-related health spending surpassed $1 trillion in 2024, representing 12% of global health expenditure.
How fast is the diabetes population expected to grow?
Adults with diabetes are projected to rise from 589 million in 2024 to 853 million by 2050, an increase of about 45% and about 1.4% CAGR over 2024–2050.
Which companies lead the diabetes industry?
Eli Lilly and Company stands out for diabetes and cardiometabolic medicines because it reported $65.179 billion in 2025 revenue driven partly by Mounjaro, while Insulet focuses on tubeless insulin delivery since Omnipod is available in 25 countries.
What technology shifts are shaping the market?
GLP-1 competition intensifies and weekly insulin begins reshaping basal therapy, while CGM adoption moves toward mass market and oral GLP-1 access expands.
How concentrated is GLP-1 demand among companies?
The GLP-1 segment is concentrated among a small number of large pharmaceutical companies, with Novo Nordisk reporting close to 43% of global GLP-1 volumes in 2025.
Where do market gaps show up in demand and diagnosis?
In the United States, 252 million adults were unaware they had diabetes, and U.S. incidence was 7.1/1,000 in 2025.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 21). Diabetes Industry Statistics. Gitnux. https://gitnux.org/diabetes-industry-statistics
MLA
Samuel Norberg. "Diabetes Industry Statistics." Gitnux, 21 Nov 2026, https://gitnux.org/diabetes-industry-statistics.
Chicago
Samuel Norberg. 2026. "Diabetes Industry Statistics." Gitnux. https://gitnux.org/diabetes-industry-statistics.